First truly non-invasive electromagnetic platform for solid tumors
A patented coil device that targets cancer cells electromagnetically — 60 minutes a day, no contact, no surgery. Launching with DIPG, the deadliest pediatric brain cancer.
The urgent gap
Current energy-based cancer therapy demands near-continuous wear, invasive hardware, or both. Children with DIPG have a 1% five-year survival rate and zero approved non-invasive options.
of all cancers are solid tumors — one physics-based mechanism can address the whole class
five-year survival in DIPG (diffuse intrinsic pontine glioma), a lethal pediatric brain cancer
approved non-invasive DIPG therapies today
A patented coil platform that targets cancer cells electromagnetically
- —Locks onto voltage-gated ion channels of cancer cells
- —Drives selective cancer-cell apoptosis; healthy tissue unaffected
- —Truly non-invasive: coil disk + signal generator, no electrodes, no shaved scalp
- —60 min/day session vs. 18 h/day for the incumbent
- —Same hardware for any solid tumor — one platform, many indications
Low-cost reusable hardware on a monthly rental model → recurring revenue per patient, scalable to home use; a DIPG regulatory beachhead (HDE) opens the full solid-tumor market.
Energy-based oncology is proven — but today it is burdensome. We remove the burden.
From granted patent to living proof in animals
Core device patent filed and granted in the United States
Built and deployed: 500 early-adoption pet patients treated for inflammatory conditions
3 veterinary solid-tumour patients in remission under compassionate use; 60 min/day protocol established
Non-confidential rodent DIPG/DMG study brief issued; CROs and academic labs engaged for the first independent sham-controlled study
Veterinary results only. They do not establish safety or efficacy in humans.
Granted US device patent in hand
24 months from Seed to a DIPG Humanitarian Device Exemption trial
DIPG/DMG cell-line screen and dosimetry; CRO contracted; method-of-use filings
Oncopig safety study; sham-controlled rodent DIPG efficacy readout
Veterinary efficacy data complete; HDE pre-submission with FDA; site prep
DIPG HDE trial opened; initial patient recruitment
Team
7 years of PEMF R&D · named inventor on the granted US device patent · med-tech founder
Regulatory lead · research & development operations
Staff Neuro-Oncologist, SickKids Paediatric Brain Tumour Program · Canada Research Chair in Pediatric Neuro-Oncology · Associate Professor, University of Toronto
Supported by an extended advisory network in medical technology, regulatory affairs and neuro-oncology.
Partners & investors
Raising a $3M Seed, milestone-gated across two years, to fund preclinical and veterinary efficacy data and open a DIPG HDE trial. Full diligence deck, exposure protocols, head-to-head data and device specifications available under NDA.
We are selecting a CRO or academic laboratory to design and quote the first independent sham-controlled rodent DIPG/DMG study. VCtronics supplies the exposure hardware; the provider advises on model, endpoints and execution.